Tapentadol Abuse Potential: A Postmarketing Evaluation Using a Sample of Individuals Evaluated for Substance Abuse Treatment

Butler, Stephen F.; McNaughton, E.C.; Black, Ryan A.

doi:10.1111/pme.12524

Cited by 69 publications

(63 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Public health authorities have called for development of analgesic formulations with no, or reduced, abuse potential [5]. A post‐marketing evaluation of the abuse liability of tapentadol examined the relative abuse risk of this molecule and selected comparators [6]. The present work complements and extends these findings using a unique data source—Internet discussion of prescription pain relievers by recreational drug abusers at online forums.…”

Section: Introductionmentioning

confidence: 78%

Assessing Abuse Potential of New Analgesic Medications Following Market Release: An Evaluation of Internet Discussion of Tapentadol Abuse

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 78%

Assessing Abuse Potential of New Analgesic Medications Following Market Release: An Evaluation of Internet Discussion of Tapentadol Abuse

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Specifically, Mayer and Höllt [45] correctly proposed that the “vast number of non-coding, intronic or promoter polymorphisms in the opioid receptors may influence addictive behavior, but these polymorphisms are far less studied, and their physiological significance remains to be demonstrated.” Most importantly, these companies have never performed research to show whether or not their genetic full panel test significantly predicts anything, let alone addiction risk or any associated behaviors.…”

Section: Genetic Addiction Risk Scorementioning

confidence: 99%

“…The variants or SNPs, incorporating point mutations, were selected to reveal a hypodopaminergic trait. In considering validation, we joined the creators of the Addiction Severity Index-Media Version (ASI-MV), a test required in 18 states, for both alcohol and drug severity risk scores [45]. …”

Section: Genetic Addiction Risk Scorementioning

confidence: 99%

Customized DNA–directed precision nutrition to balance the brain reward circuitry and reduce addictive behaviors

Blum¹,

Febo²,

Braverman³

et al. 2018

Precision Medicine in Cancers and Non-Communicable Diseases

View full text Add to dashboard Cite

DNA Customization of nutraceutical products is here. In the truest sense, “Gene Guided Precision Nutrition™” and KB220 variants (a complex mixture of amino–acids, trace metals, and herbals) are the pioneers and standard-bearers for a state of the art DNA customization. Findings by both, Kenneth Blum, Ph.D. and Ernest Noble, Ph.D. concerning the role of genes in shaping cravings and pleasure- seeking, opened the doors to comprehension of how genetics control our actions and effect our mental and physical health. Moreover, technology that is related to KB220 variants in order to reduce or eradicate excessive cravings by influencing gene expression is a cornerstone in the pioneering of the practical applications of nutrigenomics. Continuing discoveries have been an important catalyst for the evolution, expansion, and scientific recognition of the significance of nutrigenomics and its remarkable contributions to human health. Neuro-Nutrigenomics is now a very important field of scientific investigation that offers great promise to improving the human condition. In the forefront is the development of the Genetic Addiction Risk Score (GARS™), which unlike 23andMe, has predictive value for the severity of drug and alcohol abuse as well as other non-substance related addictive behaviors. While customization of neuronutrients has not yet been commercialized, there is emerging evidence that in the future, the concept will be developed and could have a significant impact in addiction medicine.

show abstract

“…The variants or SNPs, including point-mutations, were chosen to reflect a hypodopaminergic trait. In terms of validation we partnered with the developers of the Addiction Severity Index- Media Version (ASI-MV), a test mandated in 13 states, for both alcohol and drug severity risk scores [31]. …”

Section: Can We Predict Risk Using Genetic Testing?mentioning

confidence: 99%

Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility

Blum¹,

Hauser²,

Fratantonio³

et al. 2015

Addiction Genetics

View full text Add to dashboard Cite

The Brain Reward Cascade (BRC) is an interaction of neurotransmitters and their respective genes to control the amount of dopamine released within the brain. Any variations within this pathway, whether genetic or environmental (epigenetic), may result in addictive behaviors as well as altered pain tolerance. While there are many studies claiming a genetic association with addiction and other behavioral infractions, defined as Reward Deficiency Syndrome (RDS), not all are scientifically accurate and in some case just wrong. Albeit our bias, we discuss herein the facts and fictions behind molecular genetic testing in RDS (including pain and addiction) and the significance behind the development of the Genetic Addiction Risk Score (GARSPREDX™), the first test to accurately predict one's genetic risk for RDS.

show abstract

Tapentadol Abuse Potential: A Postmarketing Evaluation Using a Sample of Individuals Evaluated for Substance Abuse Treatment

Abstract: Tapentadol abuse was seen infrequently in this study and, on a prescription basis, was less likely to be abused than most of the examined Schedule II analgesics.

Cited by 69 publications

References 33 publications

Assessing Abuse Potential of New Analgesic Medications Following Market Release: An Evaluation of Internet Discussion of Tapentadol Abuse

Assessing Abuse Potential of New Analgesic Medications Following Market Release: An Evaluation of Internet Discussion of Tapentadol Abuse

Customized DNA–directed precision nutrition to balance the brain reward circuitry and reduce addictive behaviors

Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility

Contact Info

Product

Resources

About